NCT07008963View on ClinicalTrials.gov

Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Metastatic Breast Cancer
Interventions
OTHER

non-interventional

This is a non-interventional, observational study

Trial Locations (1)

94065

RECRUITING

Research Site, Redwood Shores

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY